Sheet 1 of 1								2011		
Form PTO/SB/08A							L NO. 3,975	SFP 2 2 2	1098 1098	
LIST		EFERENCES CITE .PPLICANT(S)	≣D	APPLICANT(S) Avi SHOSHAN et al.			THE STATE OF THE S	254 Z 3 Z	1002 y	
Date Submitted	: Sepe	ember 23, 2002		FILING DATE July 20, 2001			GROUP To be assign	RODEMA	BKOK	
				S. PATENT DOCUMENTS						
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE (M/D/Y)	NAME	CLAS	S	SUBCLASS	FILING I		
	<u> </u>							-	6	
-			*				9			
-				7.						
				EIGN PATENT DOCUMENT						
	<u> </u>	DOCUMENT NUMBER	DATE (M/D/Y)	COUNTRY	CLASS	3	SUBCLASS	TRANSL YES		
CW	A01	WO98/53319	11/26/98	WIPO			-	0		
CW	A02	WO01/57252A2	8/9/01	WIPO	_		-1	Ŋ		
			*				£ ,	M is		
			2=	9			TECH CENTER 18	10 P		
							岩台	4 200	n	
0							Solc	2	Ö	
		-		ų.			ge	3		
		*		,		,			-	
$\overline{}$		OTHER DOC	JMENT(S) (Ir	ncluding Author, Title, Date,	, Pertinen	t Pages,	Etc.)		<u> </u>	
<u>C.M.</u>	A03	BLACK	Cell 103: 36	67-370 (2000)						
(le	A04	CROFT et al.	Nature Genetics 24: 340-341 (2000) Separation Separ							
$\frac{2}{2}$	A05	ELBASHIR et al.	Genes & Development 15: 188-200 (2001)							
C'M	A07	al. LOCKHART et al.	Genome Research 8: 524-530 (1988)							
X-4-	A07	MIRONOV et al.	Bio/Technology 14(13): 1675-1680 (1996) Genome Research 9(12): 1288-1293 (1999)							
\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	A09	SCHENA et al.	Genome Research 9(12): 1288-1293 (1999) 100/02900 Science 270: 467-470 (1995)							
2	A10	VARGA et al.	Immunology Letter 69: 217-224 (1999)							
Tur	A11	ZAMORE, ef al.	Cell 101; 25							
EXAMINER	(-)	in this	1 6	DATE CONSI	DERED	7.	2./31	1/13		
		VI 10 1 1000	\sim 1 \wedge	JOOURN 12		<i>.</i> '.'	-	- 		

*EXAMINER: Initial if reference opnsidered, whether or not citation is in conformance with MPEP 609; Draw line through citation is not considered. Include copy of this form with next communication to applicant.

JUN 2 0 2003 2

Please type a plus sign (+) inside this box $\rightarrow \boxtimes$

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE

Vol. 409, pp. 860-921;

291, pp. 1304-1351.

** PTO/SB/08A (10-96) Approved for use through 10/31/99 OMB 0651-0031

Application Number

First Named Inventor

Filing Date

Complete if Known

09/908,975

July 20, 2001

Shoshan et al

Patent and Trademark Office: U.S. DEPARTMENT Of COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	CTAT	TEMENT BY APPLICANT				iosnan et al		
	SIA	EMENT DI ATTEICANT				537		
	(1	ise as many sheets as necessary) .		Examiner Name				
Sheet	1	of	1	Attorney Docket Number	25574			
		OTHER PRIOR ART – NON I						
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LE item (book, magazine, journal, serial sympos publisher, city an	TTERS), title of ium, catalog, etc. d/or country whe	the article (when appropriate),) date, page(s), volume-issue n re published.	umber(s),	T ²		
TW.	AA	item (book, magazine, journal, serial sympos publisher, city an Fire et al., Potent and Specific Genetic Caenorhabditis Elegans, Nature, 19 Fo	Interference ebruary 1998,	by Double-Stranded RN Vol., 391, pp. 306-311;	A in 7 E	CEIVE		
Ch	AB	Caenorhabditis Elegans, Nature, 19 Fe Elbashir et al., Duplexes of 21-Nucleo Cultured Mammalian Cell, Nature, 24 Bass, RNA Interference, The Short Ans pp. 426-429:	tide RNAs M May 2000, V	Iediate RNA Interference Vol., 411, pp. 494-498; 7	in OU.	V 2 3 2003		
$\overline{\mathcal{C}}$	AC	** '				ER 1600/290		
Cu	AD	Mironov et al., Frequent Alternative S 1999: 9:1288-1293;	plicing of Hu	iman Genes, Genome Res	search,			
CIL	ME	Initial Sequencing and Analysis of the	Human Gene	ome, Nature, 15 February	2001,			

Venter et al., The Sequence of the Human Genome, Science, 16 February 2001, Vol.

Examiner Signature Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the Individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patient and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patients, Washington, DC 20231.

^{1.} Unique citation designation number. 2. Applicant is to place a check mark here if English language Translation is attached.